Rifaximin for Irritable Bowel Syndrome: A Meta-Analysis of Randomized Placebo-Controlled Trials

The current treatments for irritable bowel syndrome (IBS) are suboptimal. The findings of previous studies of rifaximin treatment for IBS may have differed due to variations in study design. Our study aimed to determine the therapeutic and adverse effects of rifaximin treatment for IBS based on a me...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jun, Zhu, Wenhua, Liu, Wenhui, Wu, Yingqiao, Wu, Benyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2016
Materias:
4500
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5291563/
https://www.ncbi.nlm.nih.gov/pubmed/26825893
http://dx.doi.org/10.1097/MD.0000000000002534

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5291563/
https://www.ncbi.nlm.nih.gov/pubmed/26825893
http://dx.doi.org/10.1097/MD.0000000000002534

Ejemplares similares